The absolute bioavailability of desvenlafaxine in healthy subjects

Journal of Bioequivalence and Bioavailability

Volumn 4, Issue 2, 2012, Pages 18-23

  Nichols, Alice I ^a   Behrle, Jessica A ^b   Richards, Lyette S ^a   Parker, Vernon D ^b   Posener, Joel A ^a   Fruncillo, Richard ^a   Paul, Jeffrey ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

Bioavailability; Desvenlafaxine; Intravenous; Major depressive disorder; O desmethylvenlafaxine; Pharmacokinetics

Indexed keywords

DESVENLAFAXINE; DRUG METABOLITE; GLUCURONIDE; N,O DIDESMETHYLVENLAFAXINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; ENANTIOMER; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

EID: 84861158346     PISSN: None     EISSN: 09750851     Source Type: Journal    
DOI: 10.4172/jbb.1000105     Document Type: Article

References (15)

1. Howell SR, Husbands GE, Scatina JA, Sisenwine SF (1993) Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23: 349-359.
2. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, et al. (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35: 4493-4497.
3. Pristiq, package insert, (2008) Philadelphia, PA, Wyeth Pharmaceuticals.
4. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, et al. (2006) Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318: 657-665.
5. Physicians' Desk Reference, 62 ed (2007) Thomson Healthcare, Montvale, NJ.
6. Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, et al. (2008) Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 23: 243-253.
7. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, et al. (2008) Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 24: 1877-1890.
8. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D (2009) Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 31: 1405-1423.
9. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, et al. (2006) CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31: 493-502.
10. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, et al. (2009) Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 29: 39-43.
11. Silkey B, Preskorn SH, Golbeck A, Shah R, Neff M, et al. (2005) Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract 11: 16-26.
12. DeMaio W, Kane CP, Nichols AI, Jordan R (2011) Metabolism studies of desvenlafaxine. J Bioequiv Availab 3:1 51-160.
13. Behrle JA, Nichols AI, McGrory SB, Raible D (2005) An open-label, randomized, single-dose, dose-proportionality study of oral doses of a sustained-release formulation of desvenlafaxine succinate in healthy subjects. Clin Pharmacol Ther 77: P82.
14. Richards LS, Behrle JA, Nichols AI, Fruncillo RJ, Paul J (2005) An ascending multiple-dose study of the safety and pharmacokinetics of a sustained-release formulation of desvenlafaxine succinate in healthy subjects. Clin Pharmacol Ther 77: P84.
15. Patat A, Troy S, Burke J, Trocherie S, Danjou P, et al. (1998) Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. J Clin Pharmacol 38: 256-267.